NSI 189 - Neuralstem

Drug Profile

NSI 189 - Neuralstem

Alternative Names: NSI-189; NSI-189 phosphate

Latest Information Update: 12 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Neuralstem
  • Developer Neuralstem; University of California, San Diego
  • Class Antidepressants; Piperazines; Pyridines; Small molecules
  • Mechanism of Action Neurogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Major depressive disorder
  • Preclinical Alzheimer's disease; Angelman syndrome; Brain injuries; Cognition disorders; Diabetic neuropathies; Neurodegenerative disorders; Post-traumatic stress disorders; Stroke

Most Recent Events

  • 05 Dec 2017 Safety and efficacy data from a phase II trial in Major depressive disorders released by Neuralstem
  • 07 Sep 2017 Neuralstem receives patent allowance for NSI-189 in USA
  • 25 Jul 2017 The primary endpoint was not met in a phase II trial in Major Depressive Disorder
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top